Organization | Canisius-Wilhelmina Hospital

Canisius-Wilhelmina Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Nijmegen Netherlands (1850)

Organization Overview

First Clinical Trial

2004

NCT00999232

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Canisius-Wilhelmina Hospital | Canisius-Wilhelmina Zeikenhuis | Canisius Wilhelmina Ziekenhuis Nijmegen; Department of Internal Medicine

Active Ingredients

Drugs in Phase 4 Trials (6)

doxazosin (cardura) (1 trial)

erythromycin (ilosone) (1 trial)

mifepristone (mifeprex) (1 trial)

misoprostol (cytotec) (1 trial)

phenoxybenzamine hydrochloride (dibenzyline) (1 trial)

Drugs in Phase 3 Trials (2)

albuterol (proventil) (1 trial)

testosterone (delatestryl) (1 trial)

Drugs in Phase 2 Trials (3)

hydroxocobalamin (cyanokit) (1 trial)

lysergic acid diethylamide (1 trial)

vitamin k2 (1 trial)

Drugs in Other Trials (1)

procalcitonin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Headache (Phase 2)

Migraine Disorders (Phase 2)

Migraine with Aura (Phase 2)

Migraine without Aura (Phase 2)

Pancreatitis (Phase 4)

Pheochromocytoma (Phase 4)

Pneumonia (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 12